# US 2010/0167328 A1 · Blood cell separation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0167328 A1 - Document ID: US20100167328A1 - Status: Published application - Kind: A1 - Application number: 12/376,995 - Filed: 2007-08-10 - Published: 2010-07-01 - Earliest claimed: 2006-08-11 - Inventors: Neil David Avent; Zoe Eileen Plummer; David John Head - Web page: https://patentgrep.com/patent/US20100167328A1 ## CPC - G01N 33/6893: {related to diseases not provided for elsewhere} - G01N 2800/38: Pediatrics - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract There is provided a method of isolating foetal cells from an isolated sample of maternal blood, the method comprising identifying cells having a different expression pattern of at least one foetal marker compared to the expression pattern of the marker in an equivalent maternal cell and selecting the identified cells, characterised in that the foetal marker is selected from: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, Peroxiredoxin 2. There is also provided a method of cultivating foetal cells and a foetal cell isolation kit. ## Claims ### Claim 1 A method of isolating foetal cells from a sample of maternal blood, the method comprising: identifying cells having a different expression pattern of at least one foetal marker compared to the expression pattern of the marker in an equivalent maternal cell; and selecting the identified cells, wherein said at least one foetal marker is selected from the group consisting of: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, and Peroxiredoxin 2. ### Claim 2 (depends on 1) A method according to claim 1 wherein the method comprises identifying cells expressing at least one foetal marker on the cell surface and selecting those cells. ### Claim 3 (depends on 1, 2) A method according to claim 1 or 2 wherein the method comprises selecting cells expressing one foetal marker on the cell surface. ### Claim 4 (depends on 2) A method according to claim 2 further comprising separating the identified cells from cells not expressing the foetal marker on the cell surface. ### Claim 5 (depends on 2) A method according to claim 2 wherein the foetal marker is HSP-60. ### Claim 6 (depends on 1) A method according to claim 1 wherein the at least one foetal marker is a monoamine oxidase. ### Claim 7 (depends on 6) A method according to claim 6 further comprising separating the identified cells from cells not expressing the foetal marker. ### Claim 8 (depends on 2) A method according to claim 2 further comprising the step of: separating the selected foetal cells from non-equivalent maternal cells having the same expression pattern of the at least one foetal marker. ### Claim 9 (depends on 1) A method according to claim 1 wherein cells are identified which express HSP-60 on the cell surface and an increased amount of at least one foetal marker selected from the group consisting of: a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, and uncharacterised protein Cxorf57; or a decreased amount of at least one foetal marker selected from the group consisting of: Extracellular matrix protein 2 precursor protein, Peroxiredoxin 1, and Peroxiredoxin 2. ### Claim 10 (depends on 1) method according to claim 1 wherein cells are identified which express a monoamine oxidase and an increased amount of at least one foetal marker selected from the group consisting of: glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, and uncharacterised protein Cxorf57; or a decreased amount of at least one foetal marker selected from the group consisting of: Extracellular matrix protein 2 precursor protein, Peroxiredoxin 1, and Peroxiredoxin 2. ### Claim 11 (depends on 1) A method according to claim 1 wherein the foetal marker is a monoamine oxidase. ### Claim 12 (depends on 11) A method according to claim 11 wherein the monoamine oxidase is MAOA. ### Claim 13 (depends on 11) A method according to claim 11 wherein the monoamine oxidase is MAOB. ### Claim 14 (depends on 1) A method according to claim 1 wherein the foetal marker is glutamine synthase. ### Claim 15 (depends on 1) A method according to claim 1 wherein the foetal marker is Ara-70. ### Claim 16 (depends on 1) A method according to claim 1 wherein the foetal marker is Ara-54. ### Claim 17 (depends on 1) A method according to claim 1 wherein the foetal marker is FLJ20202. ### Claim 18 (depends on 1) A method according to claim 1 wherein the foetal marker is DCN-I protein. ### Claim 19 (depends on 1) A method according to claim 1 wherein the foetal marker is RAB5A. ### Claim 20 (depends on 1) A method according to claim 1 wherein the foetal marker is HSP-7C. ### Claim 21 (depends on 1) A method according to claim 1 wherein the foetal marker is EF1A1. ### Claim 22 (depends on 1) A method according to claim 1 wherein the foetal marker is GRP78. ### Claim 23 (depends on 1) A method according to claim 1 wherein the foetal marker is MYL4. ### Claim 24 (depends on 1) A method according to claim 1 wherein the foetal marker is DnaJ homolog subfamily B member 14. ### Claim 25 (depends on 1) A method according to claim 1 wherein the foetal marker is Vinculin. ### Claim 26 (depends on 1) A method according to claim 1 wherein the foetal marker is Desmoplakin. ### Claim 27 (depends on 1) A method according to claim 1 wherein the foetal marker is AMMECR1-like protein. ### Claim 28 (depends on 1) A method according to claim 1 wherein the foetal marker is Extracellular matrix protein 2 precursor protein. ### Claim 29 (depends on 1) A method according to claim 1 wherein the foetal marker is uncharacterised protein Cxorf57. ### Claim 30 (depends on 1) A method according to claim 1 wherein the foetal marker is Peroxiredoxin 1. ### Claim 31 (depends on 1) A method according to claim 1 wherein the foetal marker is Peroxiredoxin 2. ### Claim 32 (depends on 1) A method according to claim 1 wherein the maternal blood is in the form of an isolated sample. ### Claim 33 (depends on 1) A method according to claim 1 wherein the maternal blood is suitable to be returned to a subject from which it has been obtained. ### Claim 34 A method of isolating foetal cells from maternal blood, the method comprising: identifying cells having a different expression pattern of at least one foetal marker compared to the expression pattern of the marker in an equivalent maternal cell; and selecting the identified cells, wherein the foetal marker is selected from the group consisting of: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, and Peroxiredoxin 2. ### Claim 35 A method of cultivating foetal cells, the method comprising: enriching cells having a different expression pattern of at least one foetal marker compared to the expression pattern of the marker in an equivalent maternal cell, the foetal marker being selected from the group consisting of: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised 1 protein Cxorf57, Peroxiredoxin 1, and Peroxiredoxin 2. ### Claim 36 (depends on 35) A method according to claim 35 wherein the foetal cells are isolated after identifying and selecting cells that have the different expression pattern. ### Claim 37 (depends on 1) A cell sample containing isolated cells obtainable by a method comprising a method according to claim 1. ### Claim 38 (depends on 1) A cell sample containing isolated cells obtained by a method comprising a method according to claim 1. ### Claim 39 (canceled) ### Claim 40 (depends on 1) A method according to claim 1 wherein the cells are erythroblasts. ### Claim 41 A foetal cell isolation kit, comprising: means for detecting whether a cell has a different expression pattern of at least one foetal marker compared to the expression pattern of the marker in an equivalent maternal cell, and means of separating a cell having the different expression pattern of the at least one foetal marker from a cell which does not have the different expression pattern of the at least one foetal marker, wherein the foetal marker is selected from the group consisting of: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, and Peroxiredoxin 2. ### Claim 42 (canceled) ### Claim 43 (canceled) ### Claim 44 An apparatus comprising: means for detecting whether a cell has a different expression pattern of at least one foetal marker compared to the expression pattern in a maternal cell, and means of separating a cell having the different expression pattern of the at least one foetal marker from a cell which does not have the different expression pattern of the at least one foetal marker, wherein the foetal marker is selected from the group consisting of: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, and Peroxiredoxin 2. ### Claim 45 A method of determining that a cell is a foetal cell, the method comprising: detecting in the cell at least one foetal marker having a different expression pattern compared to the expression pattern in an equivalent maternal cell, wherein the foetal marker is selected from the group consisting of: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, human hypothetical proteins MGC 10526 or MGC 10233, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, and Peroxiredoxin 2.